Exicure Performance dei guadagni passati
Il passato criteri di controllo 0/6
Exicure has been growing earnings at an average annual rate of 14.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 12.5% per year.
Informazioni chiave
14.9%
Tasso di crescita degli utili
29.8%
Tasso di crescita dell'EPS
Biotechs Crescita del settore | 17.0% |
Tasso di crescita dei ricavi | 12.5% |
Rendimento del capitale proprio | -506.6% |
Margine netto | -1,634.4% |
Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding
Aug 29Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities
Sep 26Exicure Q2 GAAP loss per share narrows, revenue up
Aug 15Exicure regains compliance with Nasdaq's minimum bid price requirement
Jul 20Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance
Jun 29Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Aug 25Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Mar 10Ripartizione dei ricavi e delle spese
Come Exicure guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Jun 24 | 1 | -8 | 6 | 0 |
31 Mar 24 | 1 | -13 | 11 | 0 |
31 Dec 23 | 0 | -17 | 13 | 0 |
30 Sep 23 | 22 | 3 | 13 | 0 |
30 Jun 23 | 24 | 3 | 13 | 0 |
31 Mar 23 | 26 | 1 | 11 | 0 |
31 Dec 22 | 29 | -3 | 11 | 0 |
30 Sep 22 | 9 | -35 | 13 | 0 |
30 Jun 22 | 3 | -53 | 13 | 0 |
31 Mar 22 | 1 | -60 | 13 | 0 |
31 Dec 21 | 0 | -64 | 13 | 0 |
30 Sep 21 | -2 | -63 | 12 | 0 |
30 Jun 21 | 4 | -48 | 11 | 0 |
31 Mar 21 | 8 | -38 | 10 | 0 |
31 Dec 20 | 17 | -25 | 10 | 0 |
30 Sep 20 | 17 | -22 | 9 | 0 |
30 Jun 20 | 15 | -19 | 9 | 0 |
31 Mar 20 | 10 | -20 | 9 | 0 |
31 Dec 19 | 1 | -26 | 9 | 0 |
30 Sep 19 | 1 | -21 | 8 | 0 |
30 Jun 19 | 1 | -21 | 8 | 0 |
31 Mar 19 | 0 | -22 | 8 | 0 |
31 Dec 18 | 0 | -22 | 8 | 0 |
30 Sep 18 | 2 | -21 | 8 | 0 |
30 Jun 18 | 5 | -18 | 8 | 0 |
31 Mar 18 | 7 | -14 | 8 | 0 |
31 Dec 17 | 10 | -11 | 7 | 0 |
30 Sep 17 | 8 | -13 | 6 | 0 |
30 Jun 17 | 6 | -15 | 5 | 0 |
31 Mar 17 | 3 | -16 | 4 | 0 |
31 Dec 16 | 1 | -17 | 4 | 0 |
31 Dec 15 | 2 | -6 | 5 | 0 |
Guadagni di qualità: XCUR is currently unprofitable.
Margine di profitto in crescita: XCUR is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: XCUR is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.
Accelerare la crescita: Unable to compare XCUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: XCUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendimento del capitale proprio
ROE elevato: XCUR has a negative Return on Equity (-506.63%), as it is currently unprofitable.